Richard Bade and Malcolm McLeod explain to LCGC International how chromatography detects drug trends in wastewater.
News|Articles|November 19, 2024
Current and Future Advancements in PFAS Research
Author(s)SPEX
This white paper explores the health risks, environmental impacts, and detection technologies associated with PFAS, along with the latest advancements in PFAS research. It also provides an overview of the regulatory landscape and emphasizes the crucial role of companies like ZeptoMetrix® in supplying PFAS reference materials, which are essential for ensuring the accuracy of testing. Lastly, the paper outlines key areas for future PFAS research.
Related to this article
In this fifth part of " Conversations with Michael Dong," a series on fundamentals of HPLC in pharmaceutical analysis, LCGC International’s "Perspectives in HPLC" column editor discusses how to overcome challenges with reversed-phase chromatography in drug analysis.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) and microbiome data reveal kidney markers of diabetic disease.
Ultrahigh-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) shows Maresin1 drops in heatstroke and may protect the heart.
This week on Chromatography Online, leading experts shared practical insights with LCGC International on sustainable affinity methods, siRNA impurity profiling, nontarget screening, peptide tech transfer, and AI in separation science.
Liquid chromatography–mass spectrometry (LC–MS) was used to determine if there is a link between artificial sweeteners and breast cancer.
Chiral gas chromatography–mass spectrometry (GC–MS) shows how heat and storage alter linalool in blueberry juice.
Anneli Kruve reports that toxicity predictions from MS2-derived molecular fingerprints outperform spectral-similarity methods in nontarget screening of food.
Trending on LCGC International
1
Prioritizing Unknowns in Nontarget Screening of Food Samples
2
Conversations with Michael Dong: Overcoming Challenges with Reversed-Phase Chromatography in Drug Analysis
3
Conversations with Michael Dong: Buffers for Mobile Phase A in Pharmaceutical Analysis
4
LC–MS/MS Finds Diabetic Kidney Disease Markers
5